Mobile

A Phase III Open Label, Randomized Parallel Two-Arm Multi Center Study of E7389 versus ‘Treatment of Physician’s Choice’ in Patients with Locally Recurrent or Metastatic Breast Cancer, Previously Trea...

Mise à jour : Il y a 4 ans
Référence : EUCTR2006-001949-34

A Phase III Open Label, Randomized Parallel Two-Arm Multi Center Study of E7389 versus ‘Treatment of Physician’s Choice’ in Patients with Locally Recurrent or Metastatic Breast Cancer, Previously Treated with At Least Two and a Maximum of Five Prior Chemotherapy Regimens, Including an Anthracycline and a Taxane

Femme Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To compare the overall survival (OS) of patients treated with E7389 versus the Treatment of Physician’s Choice (including anti-tumor treatment of the investigator’s choice and palliative treatment) in patients with locally recurrent or metastatic breast cancer, who have received 2-5 prior chemotherapy regimens, which must have included an anthracycline and a taxane as prior therapy and at least 2 of which must have been given for locally recurrent or metastatic disease. Patients must also be refractory to their latest chemotherapy regimen, documented by progression on or within six (6) months of therapy.

Critère d'inclusion

  • Locally recurrent or metastatic breast cancer after failure of multiple prior chemotherapy regimens

Liens